Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody

Cancer Letters

Volumn 128, Issue 2, 1998, Pages 127-135

  Vidovic D ^a   Toral, J I ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Apoptosis; B cell neoplasm; Major histocompatibility complex; Monoclonal antibodies

Indexed keywords

HLA DR ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; APOPTOSIS; HLA-DR ANTIGENS; HUMANS; LEUKEMIA, PLASMACYTIC; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLASMACYTOMA; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032546898     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00034-2     Document Type: Article

References (25)

1. Babbitt B., Allen P.M., Matsueda G., Haber E., Unanue E.R. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature. 317:1985;359-361.
2. Palacios R., Martinez-Maza O., Guy K. Monoclonal antibodies against HLA-DR antigens replace T helper cells in activation of B lymphocytes. Proc. Natl. Acad. Sci. USA. 80:1983;3456-3460.
3. Clement L.T., Tedder T.F., Gartland G.L. Antibodies reactive with class II antigens encoded for by the major histocompatibility complex inhibit human B cell activation. J. Immunol. 136:1986;2375.
4. Howard D.R., Eaves A.C., Takei F. Monoclonal antibodies to HLA-DP, DQ, and DR determinants: functional effects on the activation and proliferation of normal and EBV-transformed B cells. Exp. Hematol. 14:1986;887-895.
5. Vaickus L., Jones V.E., Morton C.L., Whitford K., Bacon R.N. Antiproliferative mechanism of anti-class II monoclonal antibodies. Cell. Immunol. 119:1989;445-458.
6. Holte H., Blomhoff H.K., Beiske K., Funderud S., Torjesen P., Gaudernack G., Stokke T., Smeland E.B. Eur. J. Immunol. 19:1989;1221.
7. Kabelitz D., Janssen O. Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation. Cell. Immunol. 120:1989;21-30.
8. Newell M.K., VanderWall J., Beard K.S., Freed J.H. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc. Natl. Acad. Sci. USA. 90:1993;10459-10463.
9. Truman J.-P., Ericson M.L., Choqueux-Séébold J.M., Charron D.J., Mooney N. Lymphocyte programmed cell death is mediated via HLA class II DR. Int. Immunol. 6:1994;887-896.
10. Vidović D., Falcioni F., Siklodi B., Belunis C.J., Bolin D.R., Ito K., Nagy Z.A. Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments. Eur. J. Immunol. 25:1995;3349-3355.
11. Ito K., Bian H.-J., Molina M., Han J., Magram J., Saar E., Belunis C., Bolin D.R., Arceo R., Campbell R., Falcioni F., Vidović D., Hammer J., Nagy Z.A. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J. Exp. Med. 183:1996;2635-2644.
12. Ritts R.E. Jr., Ruiz-Argüelles A., Weyl K.G., Bradley A.L., Weihmeir B., Jacobsen D.J., Strehlo B.L. Establishment and characterization of a human non-secretory plasmacytoid cell line and its hybridization with human B cells. Int. J. Cancer. 31:1983;133-141.
13. Cammarota G., Scheirle A., Takacs B., Doran D.M., Knorr R., Bannwarth W., Guardiola J., Sinigaglia F. Identification of a CD4 binding domain of HLA-DR molecule. Nature. 356:1992;799-801.
14. Co M.S., Avdalović N.M., Caron P.C., Avdalović M.V., Scheinberg D.A., Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J. Immunol. 148:1992;1149-1154.
15. Lampson L.A., Levy R. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 125:1980;293-299.
16. Fu X.-T., Karr R.W. HLA-DRα residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. Hum. Immunol. 39:1994;253-260.
17. S.M. Andrew, J.A. Titus, Fragmentation of immunoglobulin G, in: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober (Eds.), Current Protocols in Immunology, Greene & Wiley, New York, 1997, pp. 2.8.1-2.8.10.
18. G. Otten, W.M. Yokoyama, Flow cytometry analysis using the Becton-Dickinson FACScan, in: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober (Eds.), Current Protocols in Immunology, Greene & Wiley, New York, 1997, pp. 5.4.1-5.4.19.
19. + thymocytes by flow cytometry. J. Immunol. Methods. 137:1991;79-87.
20. A.A. Gaspari, S.I. Katz, Contact hypersensitivity, in: J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober (Eds.), Current Protocols in Immunology, Greene & Wiley, New York, 1997, pp. 4.2.1-4.2.5.
21. Cohen J.J., Duke R.C. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10:1992;267-293.
22. Roth P.A., Mikulka W.R., Smith C.U., Bolton W.E., Zhang C., Schlossman S.F. A novel marker for the measurement of apoptotic cells. Abstract #CC17 of the XVIII Congress of the International Society for Analytical Cytology. Cytometry. Suppl. 8:1996;44.
23. Waldor M.K., Hardy R.R., Hayakawa K., Steinman L., Herzenberg L.A., Herzenberg L.A. Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. Proc. Natl. Acad. Sci. USA. 81:1984;2855-2858.
24. Smith R.M., Morgan A., Wraith D.C. Anti-class II MHC antibodies prevent and treat EAE without APC depletion. Immunology. 83:1994;1-8.
25. J.F. Holland, E. Frei III, R.C. Bast Jr., D.W. Kufe, D.L. Morton, R.R. Weichselbaum, Cancer Medicine, Vol. 2, Williams & Wilkins, Baltimore, MD, 1996, pp. 2697-2828.